Lorzone (chlorzoxazone) - Drug Summary

Vertical Pharmaceuticals Inc.

Jump to Section
- THERAPEUTIC CLASS
- DEA CLASS
- ADULT DOSAGE & INDICATIONS
- ADMINISTRATION
- HOW SUPPLIED
- View All Sections...

Related Drug Information

Lorzone (chlorzoxazone)

THERAPEUTIC CLASS

Muscular analgesic (centrally acting)

DEA CLASS

RX

ADULT DOSAGE & INDICATIONS

Musculoskeletal Conditions

Adjunct to rest, physical therapy, and other measures for relief of discomfort associated w/ acute, painful musculoskeletal conditions

375mg Tab:
Usual: 1 tab tid or qid
Titrate: May increase to 2 tabs (750mg) tid or qid if adequate response is not obtained

Dosage can be reduced as improvement occurs

750mg Tab:
Usual: 1/3 tab (250mg) tid or qid. Give 2/3 tab (500mg) tid or qid for painful musculoskeletal conditions
Titrate: May increase to 1 tab (750mg) tid or qid if adequate response is not obtained

Dosage can be reduced as improvement occurs

ADMINISTRATION

Oral route

HOW SUPPLIED

Tab: 375mg, 750mg

WARNINGS/PRECAUTIONS

Serious (including fatal) hepatocellular toxicity reported rarely; d/c immediately if any signs/symptoms of hepatotoxicity or abnormal liver enzymes develop. Caution w/ known allergies or w/ history of allergic reactions to drugs; d/c if a sensitivity reaction occurs.

ADVERSE REACTIONS

Drowsiness, dizziness, lightheadedness, malaise, overstimulation.

DRUG INTERACTIONS

May have additive effect w/ alcohol or other CNS depressants.

PREGNANCY AND LACTATION

Safety not known in pregnancy/nursing.

MECHANISM OF ACTION

Muscular analgesic (centrally acting); acts primarily at the level of the spinal cord and subcortical areas of the

brain where it inhibits multisynaptic reflex arcs involved in producing and maintaining skeletal muscle spasm of varied etiology.

PHARMACOKINETICS

Absorption: T_{max}=1-2 hrs. **Metabolism:** Rapid; glucuronidation. **Elimination:** Urine (<1% unchanged).

ASSESSMENT

Assess for intolerance to chlorzoxazone, known allergies or history of allergic reactions to drugs, hepatic impairment, pregnancy/nursing status, and possible drug interactions.

MONITORING

Monitor for signs/symptoms of hepatotoxicity, sensitivity reactions, and other adverse reactions. Monitor LFTs.

PATIENT COUNSELING

Inform of the risks and benefits of therapy. Instruct to d/c immediately and contact physician if signs/symptoms of hepatotoxicity (eg, fever, rash, right upper quadrant pain, dark urine) or a sensitivity reaction (eg, urticaria, redness, itching of the skin) occur.

STORAGE

20-25°C (68-77°F).

Back to top